Evidence map›Paper›PMID 30349028›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas.

Thibault Kervarrec, Anne Tallet, Elodie Miquelestorena-Standley, Roland Houben, David Schrama, Thilo Gambichler, Patricia Berthon, Yannick Le Corre, Ewa Hainaut-Wierzbicka, Francois Aubin and 9 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04705389 (SerUM Markers in MERkel Cell Carcinoma Patients), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04705389 naactive not recruitingnot on this mapstarted 2022, after this paper: background citation

SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines

TypeinterventionalSponsorUniversity Hospital, ToursRan2022 to 2026Enrolled35ConditionsMerkel Cell CarcinomaArmsSamples
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Diagnostic Utility and Clinicopathologic Associations of Histone H3 Lysine 27 Trimethylation (H3K27me3) Immunohistochemistry for Merkel Cell Carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Gross hematuria in an immunocompromised male - A case report.International journal of surgery case reports · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Searching for biomarkers to help distinguish Merkel cell carcinoma from cutaneous small cell lung cancer with gene expression analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Thibault KervarrecDepartment of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.
Anne TalletPlatform of Somatic Tumor Molecular Genetics, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.
Elodie Miquelestorena-StandleyDepartment of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.
Roland HoubenDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.ORCID http://orcid.org/0000-0003-4538-2324
David SchramaDepartment of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.
Thilo GambichlerDepartment of Dermatology, Venereology and Allergology, University Hospital Bochum, GudrunStraße 5, 44791, Bochum, Germany.
Patricia Berthon"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.
Yannick Le CorreDermatology Department, LUNAM Université, CHU Angers, 4 rue Larrey, 49933, Angers, France.
Ewa Hainaut-WierzbickaDermatology Department, Université de Poitiers, CHU de Poitiers, 2 rue de la Milétrie, 86021, Poitiers, France.
Francois AubinDermatology Department, Université de Franche Comté, CHU Besançon, EA3181, IFR133, 2 Boulevard Fleming, 25030, Besançon, France.
Guido BensDermatology Department, CHR d'Orléans, 14 Avenue de l'hôpital, 45100, Orléans, France.
Flore Tabareau-DelalandeDepartment of Pathology, CHR d'Orléans, 14 Avenue de l'hôpital, 45100, Orléans, France.
Nathalie BenetonDermatology Department, CHR Le Mans, 194 Avenue Rubillard, 72037, Le Mans Cedex 09, France.
Gaëlle FromontDepartment of Pathology, Université de Tours, CHU de Tours, Boulevard Tonnellé, 37044, Tours, France.
Flavie ArbionDepartment of Pathology, Université de Tours, CHU de Tours, Boulevard Tonnellé, 37044, Tours, France.
Emmanuelle LeteurtreUniv. Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert Research Center-, F-59000, Lille, France.
Antoine Touzé"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.
Mahtab Samimi"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.
Serge GuyétantDepartment of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France. serge.guyetant@univ-tours.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma is a rare neuroendocrine carcinoma of the skin mostly induced by Merkel cell polyomavirus integration. Cytokeratin 20 (CK20) positivity is currently used to distinguish Merkel cell carcinomas from other neuroendocrine carcinomas. However, this distinction may be challenging in CK20-negative cases and in cases without a primary skin tumor. The objectives of this study were first to evaluate the diagnostic accuracy of previously described markers for the diagnosis of Merkel cell carcinoma and second to validate these markers in the setting of difficult-to-diagnose Merkel cell carcinoma variants. In a preliminary set (n = 30), we assessed optimal immunohistochemical patterns (CK20, thyroid transcription factor 1 [TTF-1], atonal homolog 1 [ATOH1], neurofilament [NF], special AT-rich sequence-binding protein 2 [SATB2], paired box protein 5, terminal desoxynucleotidyl transferase, CD99, mucin 1, and Merkel cell polyomavirus-large T antigen) and Merkel cell polyomavirus load thresholds (real-time PCR). The diagnostic accuracy of each marker was then assessed in a validation set of 103 Merkel cell carcinomas (9 CK20-negative cases and 15 cases without a primary skin tumor) and 70 extracutaneous neuroendocrine carcinoma cases. The most discriminant markers for a diagnosis of Merkel cell carcinoma were SATB2, NF expression, and Merkel cell polyomavirus DNA detection (positive likelihood ratios: 36.6, 44.4, and 28.2, respectively). Regarding Merkel cell carcinoma variants, cases without a primary skin tumor retained a similar immunohistochemical  profile and CK20-negative tumors displayed a different profile (decrease frequency of NF and SATB2 expression), but Merkel cell polyomavirus DNA remained detected (78% of cases by qPCR). Moreover, 8/9 (89%) CK20-negative Merkel cell carcinoma cases but only 3/61 (5%) CK20-negative extracutaneous neuroendocrine cases were positive for at least one of these markers. In conclusion, detection of SATB2 and NF expression and Merkel cell polyomavirus DNA helps distinguish between Merkel cell carcinoma classical and variant cases and extracutaneous neuroendocrine carcinomas.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, Merkel CellCarcinoma, NeuroendocrineDiagnosis, DifferentialFemaleHumansImmunohistochemistryMaleMiddle AgedSkin NeoplasmsBiomarkers, Tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.